TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Taysha Gene Therapies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Taysha Gene Therapies has not reported a dividend
No dividend per share appears in Taysha Gene Therapies's annual filings since fiscal 2019.